Carregando empresa
Just reported
Q4 FY2026 results
From Cencora's results release of 4 de novembro de 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
US$ 88,35B
+5,5% y/y
+4,2% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 2,71
-31% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 906,8M
-19% q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjustedUS$ 19,40 – US$ 19,75First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Demonstrações financeiras completas →
Construído a partir dos próprios documentos de Cencora, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
